Aridis Pharmaceuticals amends bylaws to set stockholder meeting quorum at 33.33%

Aridis Pharmaceuticals, Inc.

Board approved quorum reduction to one-third (33.33%) of shares entitled to vote.
Amendment effective December 16, 2023; intended to facilitate holding stockholder meetings.
Full text of amendment filed as Exhibit 3.1 to the Form 8-K.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Aridis Pharmaceuticals, Inc.: Amended bylaws to change quorum for stockholder meetings to one-third of shares issued and outstanding and entitled to vote (effective 2023-12-16).

Change: bylaw amendment
Effective: 2023-12-16

Exact text from the filing

On December 16, 2023, the Board of Directors of Aridis Pharmaceuticals, Inc. (the “Company”) approved an amendment of the Company’s Bylaws (the “Bylaws”) to change the quorum for stockholder meetings to equal one-third (33.33%) of the shares issued and outstanding and entitled to vote on the matters at the meeting.

View on SEC.gov

Browse all governance changes →

Source: SEC EDGAR

accession 0001493152-23-045212

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.